GlaxoSmithKline four-strain seasonal flu vaccine approved by FDA GlaxoSmithKline announced that the U.S. Food and Drug Administration has approved FLUARIX QUADRIVALENT for the immunisation of children three years and older and adults to help prevent disease caused by seasonal influenza virus subtypes A and type B contained in the vaccine. Fluarix Quadrivalent is the first intramuscular vaccine to cover against four influenza strains, the company said. GSK will make Fluarix Quadrivalent available in time for the 2013-14 flu season and and also plans to fulfill orders for its trivalent vaccines. Healthcare providers traditionally order flu vaccines about a year in advance of each flu season, the company said.
News For GSK From The Last 14 Days
Check below for free stories on GSK the last two weeks.
Ligand says partner GSK submits application for Promacta Ligand Pharmaceuticals (LGND) said its partner GlaxoSmithKline (GSK) announced today the submission of a supplemental New Drug Application to the FDA for Promacta for the treatment of cytopenias in patients with severe aplastic anaemia who have had an insufficient response to immunosuppressive therapy.